(MENAFN- ProactiveInvestors)
() has processed the first participant for its first pivotal study to validate its Circadian Heart Rate Variability technology as a depression test.
The study being conducted by the University of New South Wales and the Black Dog institute is expected to assessed all 80 planned participants assessed by the end of the third quarter.
It is expected to be completed with results published this year.
This is designed to demonstrate two primary endpoints. That Medibio’s technology provides:
- The first objective diagnostic test differentiating between melancholic and non-melancholic depression; and
- The first objective tool to determine the effectiveness of depression treatment
Validating that the company’s CHR-V technology can provide the first objective diagnostic tool between the two subtypes of depression and determine the effectiveness of treatment for both melancholic and non-melancholic depression would represent a major breakthrough.
Depression is a common illness worldwide with an estimated 350 million people affected and it is a major contributor to the global burden of disease.
Despite intensive research over many decades there is still no reliable quantitative evidence-based test for depression or to determine the effectiveness of prescribed treatment.
Proactive Investors Australia is the market leader in producing news articles and research reports on ASX emerging companies with distribution in Australia UK North America and Hong Kong / China.
Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.